Strata Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Update

Strata Skin Sciences, Inc. (NASDAQ:SSKN) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 358,994 shares, a growth of 33.4% from the January 15th total of 269,078 shares. Currently, 10.3% of the shares of the company are sold short. Based on an average daily trading volume, of 73,243 shares, the days-to-cover ratio is currently 4.9 days. Based on an average daily trading volume, of 73,243 shares, the days-to-cover ratio is currently 4.9 days. Currently, 10.3% of the shares of the company are sold short.

Strata Skin Sciences Stock Performance

Strata Skin Sciences stock traded down $0.05 during mid-day trading on Friday, reaching $0.35. The company’s stock had a trading volume of 1,479,820 shares, compared to its average volume of 412,095. Strata Skin Sciences has a 12-month low of $0.28 and a 12-month high of $3.86. The company has a market capitalization of $2.03 million, a P/E ratio of -0.13 and a beta of 0.33. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95. The firm’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.58.

Strata Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings results on Thursday, November 13th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.12). The firm had revenue of $6.93 million during the quarter, compared to analysts’ expectations of $7.72 million. Strata Skin Sciences had a negative return on equity of 476.73% and a negative net margin of 35.64%. Sell-side analysts predict that Strata Skin Sciences will post -1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SSKN has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Strata Skin Sciences from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Strata Skin Sciences currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On Strata Skin Sciences

A hedge fund recently raised its stake in Strata Skin Sciences stock. Azzad Asset Management Inc. ADV increased its stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) by 81.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,800 shares of the medical device company’s stock after purchasing an additional 9,800 shares during the period. Azzad Asset Management Inc. ADV owned approximately 0.41% of Strata Skin Sciences worth $45,000 as of its most recent SEC filing. Institutional investors own 32.43% of the company’s stock.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.